ÂÜÀòÂÒÂ×

Dr. Bialucha is a passionate life science leader with more than 15 years of experience in oncology/immuno-oncology drug discovery and preclinical development. Dr. Bialucha has served as Xilio’s chief scientific officer since August 2022 and joined Xilio as the senior vice president of research in April 2021. He joined Xilio from Immunitas Therapeutics where, as vice president of drug discovery, he led the development of a single cell genomics-based discovery platform and immuno-oncology focused therapeutic pipeline. Prior to joining Immunitas, Dr. Bialucha held roles of increasing responsibility at the Novartis Institutes for Biomedical Research, most recently leading the oncology biotherapeutics group, where he directed multiple programs towards successful entry into clinical development across a variety of modalities. Dr. Bialucha serves on the scientific advisory board for the Terri Brodeur Breast Cancer Foundation. Dr. Bialucha received his B.S. in molecular genetics from the University of Sussex and his Ph.D. in molecular cell biology from the MRC Laboratory for Molecular Cell Biology, University College London. He completed his postdoctoral training in Professor Scott Lowe’s laboratory at Cold Spring Harbor Laboratory, studying tumor suppressor gene networks using genetic mouse models of cancer.